(NASDAQ: PVLA) Palvella Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.63%.
Palvella Therapeutics's earnings in 2025 is -$15,953,000.On average, 2 Wall Street analysts forecast PVLA's earnings for 2025 to be -$3,650,464, with the lowest PVLA earnings forecast at -$5,188,543, and the highest PVLA earnings forecast at -$2,112,384. On average, 1 Wall Street analyst forecast PVLA's earnings for 2026 to be -$5,439,389, with the lowest PVLA earnings forecast at -$5,439,389, and the highest PVLA earnings forecast at -$5,439,389.
In 2027, PVLA is forecast to generate -$5,782,651 in earnings, with the lowest earnings forecast at -$5,782,651 and the highest earnings forecast at -$5,782,651.